Free Trial
OTCMKTS:CHGCY

Chugai Pharmaceutical (CHGCY) Stock Price, News & Analysis

Chugai Pharmaceutical logo
$23.83
-0.07 (-0.29%)
(As of 10/31/2024 ET)

About Chugai Pharmaceutical Stock (OTCMKTS:CHGCY)

Key Stats

Today's Range
$23.22
$24.23
50-Day Range
$22.50
$25.57
52-Week Range
$14.52
$26.00
Volume
64,177 shs
Average Volume
128,197 shs
Market Capitalization
$78.40 billion
P/E Ratio
33.10
Dividend Yield
0.80%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Chugai Pharmaceutical Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
27th Percentile Overall Score

CHGCY MarketRank™: 

Chugai Pharmaceutical scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Chugai Pharmaceutical are expected to decrease by -2.56% in the coming year, from $0.78 to $0.76 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Chugai Pharmaceutical is 33.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.26.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Chugai Pharmaceutical is 33.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 140.95.

  • Price to Book Value per Share Ratio

    Chugai Pharmaceutical has a P/B Ratio of 6.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.01% of the outstanding shares of Chugai Pharmaceutical have been sold short.
  • Short Interest Ratio / Days to Cover

    Chugai Pharmaceutical has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Chugai Pharmaceutical has recently increased by 3,333.94%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Chugai Pharmaceutical has a dividend yield of 0.81%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Chugai Pharmaceutical does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Chugai Pharmaceutical is 24.36%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Chugai Pharmaceutical will have a dividend payout ratio of 25.00% next year. This indicates that Chugai Pharmaceutical will be able to sustain or increase its dividend.

  • Read more about Chugai Pharmaceutical's dividend.
  • Percentage of Shares Shorted

    0.01% of the outstanding shares of Chugai Pharmaceutical have been sold short.
  • Short Interest Ratio / Days to Cover

    Chugai Pharmaceutical has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Chugai Pharmaceutical has recently increased by 3,333.94%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Chugai Pharmaceutical has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Chugai Pharmaceutical this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    1 people have added Chugai Pharmaceutical to their MarketBeat watchlist in the last 30 days.
Receive CHGCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chugai Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

CHGCY Stock News Headlines

War on Elon Escalates…
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
Chugai Pharmaceutical Co Ltd ADR (CHGCY)
See More Headlines

CHGCY Stock Analysis - Frequently Asked Questions

Chugai Pharmaceutical's stock was trading at $18.85 at the start of the year. Since then, CHGCY shares have increased by 26.4% and is now trading at $23.83.
View the best growth stocks for 2024 here
.

Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Today
10/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
Current Symbol
OTCMKTS:CHGCY
Fax
N/A
Employees
7,604
Year Founded
N/A

Profitability

Net Income
$2.31 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.93 billion
Cash Flow
$0.90 per share
Book Value
$3.51 per share

Miscellaneous

Outstanding Shares
3,289,980,000
Free Float
N/A
Market Cap
$78.63 billion
Optionable
Not Optionable
Beta
0.89
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (OTCMKTS:CHGCY) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners